Physician profile
Julia L Boothe
NPI 1255397824
$38,696.61
in general payments reported to CMS, 2019-2025
55 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,968 · 2020: $11K · 2021: $5,647 · 2022: $7,015 · 2023: $1,597 · 2024: $1,646 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,027 · Entertainment: $37.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,026.62 |
| Entertainment | $37.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,329.88 | 2019-2021 | |
| Abbvie INC. | $8,739.66 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Novartis Pharmaceuticals Corporation | $3,243.13 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,020.33 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Amgen INC. | $746.84 | 2019-2024 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $734.56 | 2019-2023 | Xarelto |
| Dentsply Sirona INC | $650.00 | 2022 | |
| Daiichi Sankyo INC. | $576.59 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $516.16 | 2019-2024 | Veozah |
| Novo Nordisk INC | $473.31 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Sunovion Pharmaceuticals INC. | $453.34 | 2019-2021 | |
| Pfizer INC. | $434.59 | 2019-2025 | |
| Indivior INC. | $391.48 | 2019-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $373.89 | 2024-2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $347.35 | 2022-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $338.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $320.04 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $308.80 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.21 | 2019-2022 | |
| Corcept Therapeutics | $268.46 | 2019-2023 | Korlym |
| Glaxosmithkline, LLC. | $232.44 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $216.02 | 2019-2024 | Airsupra, Breztri |
| Biogen, INC. | $211.42 | 2020-2024 | Leqembi |
| Vifor Pharma, INC. | $209.24 | 2019-2023 | Veltassa |
| Neurocrine Biosciences, INC. | $204.68 | 2022-2025 | Ingrezza |
| Amarin Pharma, INC. | $189.74 | 2019-2021 | |
| Ardelyx, INC. | $185.63 | 2023-2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $165.18 | 2021-2025 | Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $142.82 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.97 | 2019-2025 | Ofev |
| Scilex Pharmaceuticals INC. | $103.35 | 2020-2023 | Ztlido |
| Dexcom, INC. | $101.26 | 2022-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $99.73 | 2022-2024 | Gvoke Hypopen, Keveyis |
| Esperion Therapeutics, INC. | $96.19 | 2020-2022 | |
| Ucb, INC. | $94.84 | 2021-2023 | Briviact |
| Alkermes, INC. | $82.24 | 2022-2023 | Aristada, Lybalvi |
| Exact Sciences Corporation | $72.31 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $63.42 | 2024-2025 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $56.39 | 2019-2025 | |
| Shield Therapeutics INC | $53.03 | 2023-2025 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $49.69 | 2022 | |
| Smith+Nephew, INC. | $45.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.47 | 2021-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $45.06 | 2019-2021 | |
| Optos, INC. | $37.49 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Axsome Therapeutics, INC. | $31.30 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $28.63 | 2023 | Aptiom |
| Irhythm Technologies, INC. | $26.64 | 2022-2023 | Zio Xt Patch |
| Genentech USA, INC. | $24.68 | 2020 | |
| Acadia Pharmaceuticals INC | $23.21 | 2023 | Daybue |
| Vertex Pharmaceuticals Incorporated | $22.89 | 2025 | |
| Nestle Healthcare Nutrition INC. | $18.14 | 2021 | |
| Hologic Sales and Service, LLC | $17.50 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.69 | 2019 | |
| Grifols USA, LLC | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Boothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.